BridgeBio Pharma Inc vs Sirius XM Holdings Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Sirius XM Holdings Inc trades at $28.51 (market cap $9.70B). The key difference: BridgeBio Pharma Inc is the larger of the two by market cap, and Sirius XM Holdings Inc pays a 3.75% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | SIRI | |
|---|---|---|
Market Cap | $16.36B | $9.70B |
Sector | Health | Media |
52-Week High | $90.17 | $32.59 |
52-Week Low | $47.29 | $19.92 |
Enterprise Value | $18.14B | $18.98B |
Dividend Yield | — | 3.75% |
Trailing returns across standard periods
Latest headlines on both assets
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →SiriusXM Holdings is now composed of two businesses: SiriusXM and Pandora. SiriusXM transmits music, talk shows, sports, and news via its two satellite radio networks, primarily to consumers in vehicles who pay a subscription fee. The firm's radios come preinstalled on a wide range of light vehicles in the U.S. and Canada. The firm acquired Pandora Media in February 2019 via an all-stock transaction. Pandora is a streaming music platform that offers an ad-supported radio option and a paid on-demand service. Liberty Media owns 80% of SiriusXM, traded through its Liberty SiriusXM Group tracking stock.
Read more on SIRI →